The future of oncolytic bacteria in cancer therapy looks promising, with ongoing research focusing on improving their efficacy and safety. Advances in genetic engineering and synthetic biology could lead to the development of more potent and specific bacterial strains. Combination therapies involving oncolytic bacteria and other treatments, such as checkpoint inhibitors, are also being explored to enhance anti-tumor responses.
